重新评估肝切除术作为局部晚期肝母细胞瘤移植手术的替代方案:系统性综述和患者个体数据汇总分析。

IF 2.4 3区 医学 Q2 HEMATOLOGY Pediatric Blood & Cancer Pub Date : 2024-09-27 DOI:10.1002/pbc.31339
Juri Fuchs, Lucas Rabaux-Eygasier, Fabian Ruping, Markus Kessler, Patrick Günther, Katrin Hoffmann, Zoltan Czigany, Christoph Michalski, Geraldine Hery, Arianeb Mehrabi, Sophie Branchereau
{"title":"重新评估肝切除术作为局部晚期肝母细胞瘤移植手术的替代方案:系统性综述和患者个体数据汇总分析。","authors":"Juri Fuchs,&nbsp;Lucas Rabaux-Eygasier,&nbsp;Fabian Ruping,&nbsp;Markus Kessler,&nbsp;Patrick Günther,&nbsp;Katrin Hoffmann,&nbsp;Zoltan Czigany,&nbsp;Christoph Michalski,&nbsp;Geraldine Hery,&nbsp;Arianeb Mehrabi,&nbsp;Sophie Branchereau","doi":"10.1002/pbc.31339","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>There is ongoing debate regarding liver transplantation (LT) versus liver resection (LR) for locally advanced hepatoblastoma. However, comparative studies are lacking. Consequently, a significant evidence gap persists, hindering the establishment of consensus guidelines. This study aimed to compare LT and LR for locally advanced hepatoblastoma, using predefined inclusion criteria to ensure comparable intervention groups.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>According to current Children's Oncology Group (COG) and SIOPEL (European Childhood Liver Tumour Study Group) recommendations, hepatoblastoma that requires LT evaluation was defined as either PRETEXT (PRE-Treatment EXTent of tumor) IV F+, POST-TEXT (POST-Treatment EXTent of tumor) IV, POST-TEXT P+, and/or POST-TEXT V+. A systematic literature search (Medline/Web-of-Science/Embase) was performed. Only patients who met the aforementioned criteria were included. Patient data were extracted individually and pooled.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 189 patients with locally advanced hepatoblastoma from 55 studies met the specified criteria, with 111 undergoing LT and 78 LR. There were no significant differences between the two groups in age, alpha-fetoprotein (AFP), and PRETEXT stages. Local recurrence was more common after LR (14% vs. 3% in LT, <i>p</i> = .008), while distant recurrence was more often observed after LT (16% vs. 5% in LR, <i>p</i> = .035). Overall survival (OS) and event-free survival (EFS) did not differ significantly between LT and LR (5-year OS: LT = 75.3% [95% confidence interval: 66.5–85.2], LR = 87.6% [80.4–95.6], <i>p </i>= .140; 5-year EFS: LT = 68.5% [59.3–79.1], LR = 71.1% [60.7–83.3], <i>p </i>= .700).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Real-life data revealed that a considerable number of patients with locally advanced hepatoblastoma underwent LR. This analysis suggests that outcomes are similar and favorable for both approaches. LR can therefore be considered an effective alternative to LT in selected cases even in locally advanced hepatoblastoma.</p>\n </section>\n </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"71 12","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31339","citationCount":"0","resultStr":"{\"title\":\"Reappraisal of liver resection as an alternative to transplantation in locally advanced hepatoblastoma: A systematic review and analysis of pooled individual patient data\",\"authors\":\"Juri Fuchs,&nbsp;Lucas Rabaux-Eygasier,&nbsp;Fabian Ruping,&nbsp;Markus Kessler,&nbsp;Patrick Günther,&nbsp;Katrin Hoffmann,&nbsp;Zoltan Czigany,&nbsp;Christoph Michalski,&nbsp;Geraldine Hery,&nbsp;Arianeb Mehrabi,&nbsp;Sophie Branchereau\",\"doi\":\"10.1002/pbc.31339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>There is ongoing debate regarding liver transplantation (LT) versus liver resection (LR) for locally advanced hepatoblastoma. However, comparative studies are lacking. Consequently, a significant evidence gap persists, hindering the establishment of consensus guidelines. This study aimed to compare LT and LR for locally advanced hepatoblastoma, using predefined inclusion criteria to ensure comparable intervention groups.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>According to current Children's Oncology Group (COG) and SIOPEL (European Childhood Liver Tumour Study Group) recommendations, hepatoblastoma that requires LT evaluation was defined as either PRETEXT (PRE-Treatment EXTent of tumor) IV F+, POST-TEXT (POST-Treatment EXTent of tumor) IV, POST-TEXT P+, and/or POST-TEXT V+. A systematic literature search (Medline/Web-of-Science/Embase) was performed. Only patients who met the aforementioned criteria were included. Patient data were extracted individually and pooled.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 189 patients with locally advanced hepatoblastoma from 55 studies met the specified criteria, with 111 undergoing LT and 78 LR. There were no significant differences between the two groups in age, alpha-fetoprotein (AFP), and PRETEXT stages. Local recurrence was more common after LR (14% vs. 3% in LT, <i>p</i> = .008), while distant recurrence was more often observed after LT (16% vs. 5% in LR, <i>p</i> = .035). Overall survival (OS) and event-free survival (EFS) did not differ significantly between LT and LR (5-year OS: LT = 75.3% [95% confidence interval: 66.5–85.2], LR = 87.6% [80.4–95.6], <i>p </i>= .140; 5-year EFS: LT = 68.5% [59.3–79.1], LR = 71.1% [60.7–83.3], <i>p </i>= .700).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Real-life data revealed that a considerable number of patients with locally advanced hepatoblastoma underwent LR. This analysis suggests that outcomes are similar and favorable for both approaches. LR can therefore be considered an effective alternative to LT in selected cases even in locally advanced hepatoblastoma.</p>\\n </section>\\n </div>\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":\"71 12\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.31339\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31339\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31339","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:关于肝移植(LT)与肝切除(LR)治疗局部晚期肝母细胞瘤的争论一直存在。然而,目前缺乏比较研究。因此,证据方面仍然存在巨大差距,阻碍了共识指南的制定。本研究旨在比较局部晚期肝母细胞瘤的肝切除术(LT)和肝切除术(LR),采用预定义的纳入标准以确保干预组的可比性:根据目前儿童肿瘤学组(COG)和欧洲儿童肝肿瘤研究组(SIOPEL)的建议,需要进行LT评估的肝母细胞瘤被定义为PRETEXT(肿瘤治疗前范围)IV F+、POST-TEXT(肿瘤治疗后范围)IV、POST-TEXT P+和/或POST-TEXT V+。进行了系统的文献检索(Medline/Web-of-Science/Embase)。只有符合上述标准的患者才被纳入。对患者数据进行了单独提取和汇总:55项研究中共有189例局部晚期肝母细胞瘤患者符合特定标准,其中111例接受了LT治疗,78例接受了LR治疗。两组患者在年龄、甲胎蛋白(AFP)和PRETEXT分期方面无明显差异。LR术后局部复发更常见(LT术后14%对3%,P = .008),而LT术后远处复发更常见(LR术后16%对5%,P = .035)。LT=75.3%[95%置信区间:66.5-85.2],LR=87.6%[80.4-95.6],P=0.140;5年无事件生存期:LT=68.5%[59.3-79.1],LR=71.1%[60.7-83.3],P=0.700):真实数据显示,相当多的局部晚期肝母细胞瘤患者接受了LR治疗。这项分析表明,两种方法的疗效相似且都很好。因此,即使是局部晚期肝母细胞瘤,LR也可被视为LT的有效替代方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Reappraisal of liver resection as an alternative to transplantation in locally advanced hepatoblastoma: A systematic review and analysis of pooled individual patient data

Background

There is ongoing debate regarding liver transplantation (LT) versus liver resection (LR) for locally advanced hepatoblastoma. However, comparative studies are lacking. Consequently, a significant evidence gap persists, hindering the establishment of consensus guidelines. This study aimed to compare LT and LR for locally advanced hepatoblastoma, using predefined inclusion criteria to ensure comparable intervention groups.

Methods

According to current Children's Oncology Group (COG) and SIOPEL (European Childhood Liver Tumour Study Group) recommendations, hepatoblastoma that requires LT evaluation was defined as either PRETEXT (PRE-Treatment EXTent of tumor) IV F+, POST-TEXT (POST-Treatment EXTent of tumor) IV, POST-TEXT P+, and/or POST-TEXT V+. A systematic literature search (Medline/Web-of-Science/Embase) was performed. Only patients who met the aforementioned criteria were included. Patient data were extracted individually and pooled.

Results

A total of 189 patients with locally advanced hepatoblastoma from 55 studies met the specified criteria, with 111 undergoing LT and 78 LR. There were no significant differences between the two groups in age, alpha-fetoprotein (AFP), and PRETEXT stages. Local recurrence was more common after LR (14% vs. 3% in LT, p = .008), while distant recurrence was more often observed after LT (16% vs. 5% in LR, p = .035). Overall survival (OS) and event-free survival (EFS) did not differ significantly between LT and LR (5-year OS: LT = 75.3% [95% confidence interval: 66.5–85.2], LR = 87.6% [80.4–95.6], = .140; 5-year EFS: LT = 68.5% [59.3–79.1], LR = 71.1% [60.7–83.3], = .700).

Conclusion

Real-life data revealed that a considerable number of patients with locally advanced hepatoblastoma underwent LR. This analysis suggests that outcomes are similar and favorable for both approaches. LR can therefore be considered an effective alternative to LT in selected cases even in locally advanced hepatoblastoma.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Pediatric Blood & Cancer
Pediatric Blood & Cancer 医学-小儿科
CiteScore
4.90
自引率
9.40%
发文量
546
审稿时长
1.5 months
期刊介绍: Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
期刊最新文献
Hypoalbuminemia and Nutritional Status in Children with Cancer. Systemic Inflammatory Response Post Alemtuzumab and Low-Dose Total Body Irradiation in Pediatric Patients With Sickle Cell Disease: A Case Series. Implications of Implementing Children's Oncology Group Risk Stratification to Patients With Rhabdomyosarcoma Treated on European Paediatric Soft Tissue Sarcoma Study Group Clinical Trial. A Rare t(X;21)(p11;q22) in Childhood Acute Myeloid Leukemia: Case Report and Literature Review. Centralized Investigator Review of Radiological and Functional Imaging Reports in Real-World Oncology Studies: The SACHA-France Experience.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1